A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher Disease

Archive ouverte

Serratrice, Christine | Stirnemann, Jérôme | Berrahal, Amina | Belmatoug, Nadia | Camou, Fabrice | Caillaud, Catherine | Billette de Villemeur, Thierry | Dalbies, Florence | Cador, Bérengère | Froissart, Roseline | Masseau, Agathe | Brassier, Anaïs | Hivert, Bénédicte | Swiader, Laure | Bertchansky, Ivan | de Moreuil, Claire | Chabrol, Brigitte | Durieu, Isabelle | Leguy Seguin, Vanessa | Astudillo, Leonardo | Humbert, Sébastien | Pichard, Samia | Marcel, Catherine | Hau Rainsard, Isabelle | Bengherbia, Monia | Yousfi, Karima | Berger, Marc

Edité par CCSD ; MDPI -

International audience. Patients with type 1 Gaucher disease (GD1) present thrombocytopenia, anemia, organomegaly, and bone complications. Most experts consider that the less aggressive forms do not require specific treatment. However, little is known about the disease course of these forms. The objective of this cross-sectional retrospective study was to compare the clinical, radiological, and laboratory characteristics of patients with less severe GD1 at diagnosis and at the last evaluation to identify features that might lead to potential complications. Non-splenectomized and never-treated patients (19 women and 17 men) were identified in the French Gaucher Disease Registry (FGDR). Their median age was 36.6 years (2.4–75.1), and their median follow-up was 7.8 years (0.4–32.4). Moreover, 38.7% were heterozygous for the GBA1 N370S variant, and 22.6% for the GBA1 L444P variant. From diagnosis to the last evaluation, GD1 did not worsen in 75% of these patients. Some parameters improved (fatigue and hemoglobin concentration), whereas platelet count and chitotriosidase level remained stable. In one patient (2.7%), Lewy body dementia was diagnosed at 46 years of age. Bone lesion onset was late and usually a single event in most patients. This analysis highlights the genotypic heterogeneity of this subgroup, in which disease could remain stable and even improve spontaneously. It also draws attention to the possible risk of Lewy body disease and late onset of bone complications, even if isolated, to be confirmed in larger series and with longer follow-up.

Suggestions

Du même auteur

Untreated patients with type 1 Gaucher disease: who are they? Resultas from the Gaucher Non-Treated study (GANT study)

Archive ouverte | Serratrice, Christine | CCSD

International audience

Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry

Archive ouverte | Nguyen, Yann | CCSD

International audience. Gaucher disease (GD) is a rare lysosomal autosomal-recessive disorder due to deficiency of glucocerebrosidase; polyclonal gammopathy (PG) and/or monoclonal gammopathy (MG) can occur in this d...

Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1

Archive ouverte | Berger, Juliette | CCSD

International audience. Background and objectives: Intravenous imiglucerase enzyme replacement therapy for Gaucher disease type 1 administered every 2 weeks is at variance with the imiglucerase plasma half-life of a...

Chargement des enrichissements...